**Question:** Argus 2 implants have been experimentally tried in:

A. Patients with retinal disorders
B. Alzheimer's disease patients
C. Patients with glaucoma
D. Patients with peripheral vision loss

**Core Concept:** Argus II is a visual prosthetic device designed for patients with severe vision loss due to retinal disorders such as retinitis pigmentosa (RP), age-related macular degeneration (AMD), or other forms of retinal dystrophies.

**Why the Correct Answer is Right:** Argus II is a retinal prosthesis that aims to restore some visual function by bypassing damaged photoreceptor cells and stimulating the surviving retinal ganglion cells (RGCs) or their axons. The device consists of an external video camera, a small processor, and a subretinal electrode array. It converts images captured by the camera into electrical signals that are transmitted to the implanted device. The signals are then delivered to the inner retina, stimulating RGCs and allowing patients to perceive visual patterns.

**Why Each Wrong Option is Incorrect:**

A. Alzheimer's disease patients: Argus II is specifically designed for patients with retinal disorders that result in severe vision loss. Alzheimer's disease primarily affects cognitive functions and memory, not vision, so the device is not suitable for these patients.

B. Glaucoma patients: Glaucoma is a neurodegenerative disease that affects the optic nerve, leading to optic atrophy and vision loss. Argus II is not designed to treat glaucoma but rather retinal disorders, which is why this option is incorrect.

C. Patients with peripheral vision loss: Argus II is intended for patients with severe vision loss due to retinal disorders, which primarily affect the central visual field. Peripheral vision loss may be caused by various conditions, making this option incorrect.

**Clinical Pearl:** Argus II is a promising tool in restoring some visual function for patients with retinal disorders. These patients should be evaluated for potential eligibility before considering implantation. The device is not suitable for patients with Alzheimer's disease, glaucoma, or peripheral vision loss due to different underlying pathologies.